journal article·2024-09Open access

PROTAC‐Mediated HDAC7 Protein Degradation Unveils Its Deacetylase‐Independent Proinflammatory Function in Macrophages

Kailibinuer Kadier, Tian Niu, Baoli Ding, Boya Chen, Xuxin Qi, Danni Chen, Xirui Cheng, Yizheng Fang, Jiahao Zhou, Wenyi Zhao, Zeqi Liu, Yi Yuan, Zhan Zhou, Xiaowu Dong, Bo Yang, Qiaojun He, Ji Cao, Li Jiang, Cheng‐Liang Zhu

Advanced Science· Volume 11· Issue 36

Abstract

Abstract Class IIa histone deacetylases (Class IIa HDACs) play critical roles in regulating essential cellular metabolism and inflammatory pathways. However, dissecting the specific roles of each class IIa HDAC isoform is hindered by the pan‐inhibitory effect of current inhibitors and a lack of tools to probe their functions beyond epigenetic regulation. In this study, a novel PROTAC‐based compound B4 is developed, which selectively targets and degrades HDAC7, resulting in the effective attenuation of a specific set of proinflammatory cytokines in both lipopolysaccharide (LPS)‐stimulated macrophages and a mouse model. By employing B4 as a molecular probe, evidence is found for a previously explored role of HDAC7 that surpasses its deacetylase function, suggesting broader implications in inflammatory processes. Mechanistic investigations reveal the critical involvement of HDAC7 in the Toll‐like receptor 4 (TLR4) signaling pathway by directly interacting with the TNF receptor‐associated factor 6 and TGFβ‐activated kinase 1 (TRAF6‐TAK1) complex, thereby initiating the activation of the downstream mitogen‐activated protein kinase/nuclear factor‐κB (MAPK/NF‐κB) signaling cascade and subsequent gene transcription. This study expands the insight into HDAC7's role within intricate inflammatory networks and highlights its therapeutic potential as a novel target for anti‐inflammatory treatments.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Histone Deacetylase Inhibitors Research · Peptidase Inhibition and Analysis · Protein Degradation and Inhibitors

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Pharmacology & Toxicology Zhejiang Province Key Laboratory of Anti‐Cancer Drug Research College of Pharmaceutical Sciences Zhejiang University Hangzhou 310058 P. R. China

Innovation Institute for Artificial Intelligence in Medicine Zhejiang University Hangzhou 310018 P. R. China

Engineering Research Center of Innovative Anticancer Drugs Ministry of Education Hangzhou 310058 P. R. China

Hangzhou Institute of Innovative Medicine Zhejiang University Hangzhou 310018 P. R. China

Cancer Center Zhejiang University Hangzhou 310058 P. R. China

Funding

National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities · China Postdoctoral Science Foundation · Natural Science Foundation of Zhejiang Province

References (60)

Show source-provided references
1. 10.1016/j.bbamcr.2014.05.01410.1016/j.bbamcr.2014.05.014 ↗
2. 10.1289/ehp.99107s566110.1289/ehp.99107s5661 ↗
3. 10.1016/B978-0-12-384929-8.00011-310.1016/B978-0-12-384929-8.00011-3 ↗
4. 10.1016/j.drudis.2015.02.00610.1016/j.drudis.2015.02.006 ↗
5. 10.1038/s41581-023-00720-110.1038/s41581-023-00720-1 ↗
6. 10.1186/s41232-022-00221-x10.1186/s41232-022-00221-x ↗
7. 10.1038/nrd300310.1038/nrd3003 ↗
8. 10.1038/s41577-019-0151-610.1038/s41577-019-0151-6 ↗
9. 10.1101/cshperspect.a01871310.1101/cshperspect.a018713 ↗
10. 10.1016/j.it.2011.04.00110.1016/j.it.2011.04.001 ↗
11. 10.1038/nrd436010.1038/nrd4360 ↗
12. 10.3390/jpm1105033610.3390/jpm11050336 ↗
13. 10.1016/j.celrep.2020.02.00710.1016/j.celrep.2020.02.007 ↗
14. 10.1073/pnas.181536511610.1073/pnas.1815365116 ↗
15. 10.1038/nchembio.31310.1038/nchembio.313 ↗
16. 10.1016/j.bmcl.2008.02.02510.1016/j.bmcl.2008.02.025 ↗
17. 10.1016/j.bmc.2019.11508710.1016/j.bmc.2019.115087 ↗
18. 10.1073/pnas.070648710410.1073/pnas.0706487104 ↗
19. 10.1093/nar/gks18910.1093/nar/gks189 ↗
20. 10.1016/j.chembiol.2022.05.00810.1016/j.chembiol.2022.05.008 ↗
21. 10.1038/cmi.2017.3210.1038/cmi.2017.32 ↗
22. 10.1111/febs.1306110.1111/febs.13061 ↗
23. 10.2217/epi.15.10610.2217/epi.15.106 ↗
24. 10.1002/cmdc.20130041310.1002/cmdc.201300413 ↗
25. 10.1038/s41392-022-00966-410.1038/s41392-022-00966-4 ↗
26. 10.1021/acs.jmedchem.2c0115910.1021/acs.jmedchem.2c01159 ↗
27. 10.1021/acs.jmedchem.2c0039710.1021/acs.jmedchem.2c00397 ↗
28. 10.1016/j.chembiol.2021.07.00210.1016/j.chembiol.2021.07.002 ↗
29. 10.1371/journal.pone.019015210.1371/journal.pone.0190152 ↗
30. 10.1111/joim.1239510.1111/joim.12395 ↗
31. 10.1007/s11908-016-0516-y10.1007/s11908-016-0516-y ↗
32. Ohl K. · J. biotechnol. Biomed. · 2011 · 2011
33. 10.1084/jem.185.9.166110.1084/jem.185.9.1661 ↗
34. Liu X. · Mol. Med. Rep. · 2018 · 17 · 5484
35. 10.1038/nchembio.122310.1038/nchembio.1223 ↗
36. 10.1016/S0092-8674(02)00861-910.1016/S0092-8674(02)00861-9 ↗
37. Yongling N. · J. Immunother. Cancer · 2020 · 810.1136/jitc-2020-000529 ↗
38. 10.1152/ajpheart.00271.201610.1152/ajpheart.00271.2016 ↗
39. 10.1016/j.cell.2020.10.03810.1016/j.cell.2020.10.038 ↗
40. 10.4155/fmc-2021-020610.4155/fmc-2021-0206 ↗
41. 10.1016/j.ejmech.2023.11524810.1016/j.ejmech.2023.115248 ↗
42. 10.3390/pharmaceutics1503081210.3390/pharmaceutics15030812 ↗
43. 10.1084/jem.173.3.69910.1084/jem.173.3.699 ↗
44. 10.1074/jbc.274.16.1068910.1074/jbc.274.16.10689 ↗
45. 10.1172/JCI1183710.1172/JCI11837 ↗
46. 10.1016/j.cellsig.2007.12.00310.1016/j.cellsig.2007.12.003 ↗
47. 10.1111/febs.1643710.1111/febs.16437 ↗
48. 10.1002/JLB.2MR1021-260R10.1002/JLB.2MR1021-260R ↗
49. 10.1371/journal.pgen.100350310.1371/journal.pgen.1003503 ↗
50. 10.1074/jbc.M113.49628110.1074/jbc.M113.496281 ↗
51. 10.1074/jbc.M110.21685310.1074/jbc.M110.216853 ↗
52. 10.3390/ijms2205271910.3390/ijms22052719 ↗
53. 10.7150/ijbs.466610.7150/ijbs.4666 ↗
54. 10.1016/j.coph.2018.05.01010.1016/j.coph.2018.05.010 ↗
55. Mi‐Sung K. · J. Neurosci. Res. · 2012 · 32
56. 10.1016/j.ebiom.2019.01.03810.1016/j.ebiom.2019.01.038 ↗
57. 10.1128/MCB.24.19.8467-8476.200410.1128/MCB.24.19.8467-8476.2004 ↗
58. 10.1074/jbc.RA118.00700610.1074/jbc.RA118.007006 ↗
59. 10.1155/2016/816727310.1155/2016/8167273 ↗
60. 10.1002/anie.20231005910.1002/anie.202310059 ↗